LUYE PHARMA (02186.HK): Antidepressant Renewed on 2026 National Reimbursement List
NewTimeSpace News: On 15 November 2026, Luye Pharma Group Ltd. (stock code: 2186) published a voluntary announcement that its Class 1 innovative drug, toludesvenlafaxine hydrochloride extended-release tablets, has been renewed on the 2026 edition of the National Reimbursement Drug List for the treatment of depression.
The product was approved in China in November 2022 and was first included in the national list in November 2024. It is described as China's first self-developed Class 1 chemical innovative drug for depression with proprietary intellectual property, the first domestic innovative drug in this therapeutic area.
As a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI), it treats depression comprehensively and steadily, markedly improving anxiety, retardation or fatigue, anhedonia and cognitive function and supporting recovery of social function, without causing drowsiness or affecting sexual function, body weight or lipid metabolism. It is currently the only SNDRI antidepressant and is recommended as first-line therapy in the 2025 Chinese guideline for the prevention and treatment of depressive disorders and the Chinese community guideline for depression.
The marketing application for generalised anxiety disorder was accepted by the Centre for Drug Evaluation of the National Medical Products Administration in January 2026. The renewal should continue to reduce patients' medication burden, widen market coverage and create room for long-term growth, the Company said, adding that it will keep advancing research in the central nervous system field.
- PINESTONE (00804.HK): Appoints Wu Yuanzheng as AI Business GM
- ALPHA PRO HLDGS (00948.HK): Clarifies 56.62M Excess Rights Shares
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output